sATP-binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells

SHAOXUAN WU1-3*, XUDONG ZHANG1,3*, MENG DONG1,3, ZHENZHEN YANG1,2, MINGZHI ZHANG1,3 and QINGJIANG CHEN1,3

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University; 2Academy of Medical Science, Zhengzhou University, Zhengzhou, Henan 450052; 3Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan 450000, P.R. China

Received December 13, 2019; Accepted July 9, 2020
DOI: 10.3892/or.2020.7722

Abstract. Extranodal natural killer (NK)/T cell lymphoma, nasal type (ENKL) is a rare type of non-Hodgkin’s lymphoma that is associated with limited effective treatment options and unfavorable survival rate, which is partly the result of multidrug resistance (MDR). The presence of side population (SP) cells-SNK-6/ADM-SP (SSP) cells has been previously used to explore mechanisms of drug resistance. ATP-binding cassette subfamily G member 2 (ABCG2) is a gene involved in MDR and is closely associated with SPs. However, the function of ABCG2 in SSP cells is unclear. The present study verified the high expression of ABCG2 in SSP cells. The IC50 values of doxorubicin, cytarabine, cisplatin, gemcitabine and l-asparaginase were tested to evaluate drug sensitivity in SSP cells with different levels of ABCG2 expression. ABCG2 was identified as a gene promoting in MDR. ABCG2 upregulated cell proliferation, increased clonogenicity, increased invasive ability and decreased apoptosis, in vivo and in vitro, when cells were treated with gemcitabine. To conclude, ABCG2 enhanced MDR and increased the typical biological characteristics associated with cancer cells in SP cells. With further investigation of the ABCG2 gene could have the potential to reverse MDR in ENKL.

Introduction
Extranodal natural killer (NK)/T cell lymphoma (ENKL) is an aggressive malignant lymphoma that occurs frequently in Asian countries, where it accounts for >10% of non-Hodgkin lymphoma (NHL), but rarely in Western countries, where it contributes to <1% of NHL cases (1-3). Localized ENKL that are treated with the incorporation of radiation and chemotherapy have good clinical outcomes with a 5-year progression-free survival rate of 61% and an overall survival rate of 72% (4). Likewise, survival has improved in disseminated disease. However, a significant percentage of metastatic ENKL will recur or exhibit refractory disease despite the initial benefit from multi-agent chemotherapy regiments (4,5). The optimal treatment for these relapsed disease is unknown (6,7) and the underlying causes for the development of ENKL are multifactorial and complex (8). Numerous tumors are comprised of a hierarchical heterogeneous structure reminiscent of side population (SP) system, with more primitive and more therapy-resistant cell types (9,10). Numerous studies have demonstrated that multidrug resistance (MDR) leads to tumor recurrence, which is hypothesized to be caused by SP cells (11,12). SP cells have been identified based on their ability to export Hoechst 33342 dye via various members of the ATP-binding cassette (ABC) membrane transporter family of proteins, which are highly expressed in SP cells (9,10,12-14).

These hypotheses led to the identification of a novel method to investigate ENKL cell lines using SP cells. We previously demonstrated that SNK-6/ADM-SP (SSP) cells that presented the mature NK cell-derived phenotype and indolent cellulating features showed higher MDR compared with SNK-6 cells (15). A noteworthy property of SSP cells is their high expression of ABCG2. Previous studies have reported that ABCG2 can decrease intracellular anticancer drug concentrations, which can contribute to chemoresistance in various types of tumors (16-18). However, the function of ABCG2 in SSP cells and ENKL progression remains unclear. Therefore, SSP cells were used to investigate the role of ABCG2 and identify a novel method to treat drug-resistant ENKL cells.
The present study aimed to analyze the relationship among ABCG2, traditional chemotherapy drugs and biological characteristics of ENKL. SSP cells in vitro and in vivo. In addition to broadening our understanding of SP cells, the present study may have identified a novel antitumor mechanism that could be used to reestablish the sensitivity of SSP cells to chemotherapy to yield clinical benefit.

Materials and methods

**Cell culture.** SNK-6 cells were established from primary lesions with nasal NK-cell lymphoma [CD3+, CD20-, CD56+, CD3 (Leu4)-, EBV-encoded small RNA+ (EBER+)] and were kindly provided by Dr Norio Shimizu of Chiba University (Chiba, Japan) (19). Their team originally established SNK-6 cell line from primary lesions of a Japanese patient with nasal T/NK-cell lymphoma (19). SNK-6 cells were CD3- CD4- CD8- CD16- CD19- CD21-CD25+ CD56+ CD57+ HLA-DR+, and exhibited the NK-cell phenotype (15,20). SSP cells were provided by Dr Xuoding Zhang of Department of Oncology, The First Affiliated Hospital of Zhengzhou University, China. Their team sorted SSP cells via a Hoechst 33342 assay from SNK-6 cells and verified the NK-cell phenotype (15). SNK-6 and SSP cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented as aforementioned (Gibco; Thermo Fisher Scientific, Inc.) and exhibited the NK-cell phenotype (15).

**Flow cytometric analysis.** To evaluate lymphocytic surface antigens, the expression levels of lymphocytic molecular markers (CD3-, CD5-, CD8-, CD56+, CD16-, Granzyne B+ and Perforin+) of SSP cells were confirmed (15,19,20). Unstained SSP cells were used for the negative control. In total, 1x10⁶/100 µl SSP cells were resuspended in PBS (HyClone; Cyvita; cat. no. SH30256.01) were incubated with anti-CD3 (5 µl ready to use; PerCP Mouse Anti-Human; cat. no. 552851), anti-CD5 (5 µl ready to use; FITC Mouse Anti-Human, cat. no. 561948) and anti-CD16 (5 µl ready to use; PE-Cy™ 7 Mouse Anti-Human; cat. no. 557747) (all BD Pharmingen™; BD Biosciences) at room temperature (RT) for 15 min. Then intrasore reagent A and B (BD IntraSure™ kit; cat. no. sc-134220; Santa Cruz Biotechnology, Inc.). GFP was used to sort infected cells using a flow cytometer (FACSAria III; BD Biosciences) and the results was analyzed by FACSDiva software version 6.1.2 (BD Biosciences) and showed that the purity of the transfected cells was >95%. In summary, six cell lines were successfully cultivated, including SSP-EV for lenti negative control, SSP-ABCG2 for ABCG2 overexpression, SSP-sh-control for lenti-sh negative control and SSP-ABCG2-sh1-3 for ABCG2-knockdown.

**Proliferation and IC₅₀ assay.** A total of 2x10⁴ cells/well seeded in 96-well plates were cultured in 90 µl RPMI-1640 medium supplemented as aforementioned (Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 12 h and then treated with 10 µl doxorubicin, cytarabine, cisplatin, gemcitabine and L-asparaginase (all Sigma-Aldrich; Merck KGaA) separately in each well with a concentration gradient for 48 h. Cell Counting Kit (CCK)-8 solution (20 µl, 5 mg/ml; Dojindo Molecular Technologies, Inc.) was used to detect the activity of cells according to the manufacturer's instructions. The absorbance was measured at 450 nm using a Multiskan FC microplate reader (Thermo Fisher Scientific, Inc.). The inhibition rate (%) was calculated as follows: (OD_control-OD_treatment/OD_control) x100. Independent experiments were repeated at least three times.

**EdU assay.** EdU (5-ethynyl-2'-deoxyuridine) is a nucleoside analog to thymidine and incorporated into DNA during active DNA synthesis (21). Flow cytometry was performed to evaluate the proliferative ability of the SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells using a Click-it™ EdU Flow Cytometry Assay kit (cat. no. C10634; Thermo Fisher Scientific, Inc.). Cells (1x10⁶ cells/ml) were cultured in 100 µl PBS (HyClone; Cyvita; cat. no. SH30256.01) and incubated with EdU (10 µM) for 2 h at 37°C in the dark. After washing with PBS (HyClone; Cyvita; cat. no. SH30256.01), centrifuging (300 x g for 5 min at RT) and dislodging the pellet, the cells were treated with Click-it™ fixative and permeabilization (cat. no. C10634; Thermo Fisher Scientific, Inc.) for 15 min at RT. Then the cells were labeled with Alexa Fluor™ 647 picolyl azide (cat. no. C10634; Thermo Fisher Scientific, Inc.) in DMSO for

pCDH-CMV-MCS-EF1-copGFP-vector, pCDH-CMV-MCS-EF1-copGFP-ABCG2, pCDH-CMV-MCS-EF1-copGFP-SSP control, pCDH-CMV-MCS-EF1-copGFP-SSP-h-control, pCDH-CMV-MCS-EF1-copGFP-SSP-SH1 (target1,1462; 5’-GCAGGATAAGCCACTCATA-3’), pCDH-CMV-MCS-EF1-copGFP-ABCG2-SH2 (target2, 2078; 5’-GACGGTCAAGGTGTGTTTT-3’), pCDH-CMV-MCS-EF1-copGFP-ABCG2-SH3 (target3, 2208; 5’-GCATTCCACGATATGGA-3’) (all Shanghai GeneChem Co., Ltd.) were cotransfected with 6.4 µg packaging plasmid pCMV deltaR8.2 (Addgene, Inc.) and 1.1 µg envelope plasmid VSVG (Addgene, Inc.) in 1,500 µl RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) into HEK293T cells (American Type Culture Collection) using 30 µl Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol at 37°C. The supernatant of HEK293T cells was discarded 8 h later and carefully added to 10 ml 1640 complete medium. After 72 h, the virus supernatant was collected, concentrated with Lenti-Concentrin Virus Precipitation solution (ExCell Bio, cat. no. EMB810A-1) and cointected with SSP cells (1x10⁶/2 ml) in the presence of 8 µg/ml polybrene (cat. no. sc-134220; Santa Cruz Biotechnology, Inc.). GFP was used to sort infected cells using a flow cytometer (FACS Aria III; BD Biosciences) and the results was analyzed by FACSDiva software version 6.1.2 (BD Biosciences) and showed that the purity of the transfected cells was >95%. In summary, six cell lines were successfully cultivated, including SSP-EV for lenti negative control, SSP-ABCG2 for ABCG2 overexpression, SSP-sh-control for lenti-sh negative control and SSP-ABCG2-sh1-3 for ABCG2-knockdown.
30 min at 37°C in the dark. Stained samples were analyzed using FACSCantoII (BD Biosciences) and FACSDiva software version 6.1.2 (BD Biosciences). The results were analyzed using FlowJo™ version 10 software (FlowJo LLC).

**Immunocytochemistry.** The SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells were fixed with 4% paraformaldehyde (for 30 min at RT), following which the cell suspension was adhered to a slide with charged substrates using acetone (10 min, RT). After washing with PBS, the 0.5% Triton X-100 (10 min, RT) was added, and then cells were blocked with 3% BSA (Sigma-Aldrich; Merck KGaA) for 1 h at RT. Cells were then incubated with the ABCG2 antibody (1:200; cat. no. sc-58222; Santa Cruz Biotechnology, Inc.) at 4°C overnight, following this, the slide was incubated with the Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody (APC) (1:100; cat. no. A-865; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Western blot analysis. Proteins of the SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells were extracted using RIPA lysis buffer (Beyotime Institute of Biotechnology; cat. no. P0013B) containing protease inhibitor, phosphatase inhibitor and EDTA. After determining the protein concentration (BCA protein concentration determination kit; Beyotime Institute of Biotechnology; cat. no. P0012), 20 µg proteins were loaded per lane on a 10% gel, resolved using SDS-PAGE and then transferred to a PVDF membrane (Beyotime Institute of Biotechnology). The membrane was blocked with 1% BSA powder (Sigma-Aldrich; Merck KGaA) for 1 h at RT. The membrane was incubated overnight at 4°C with the following primary antibodies: ABCG2 (1:500; cat. no. 42078; Cell Signaling Technology), Bax (1:1,000; cat. no. 5023; Cell Signaling Technology), BCL2 (1:1,000; cat. no. 15071; Cell Signaling Technology), Bad (1:500; cat. no. 10435-1-AP; ProteinTech Group, Inc.), Myc proto-oncogene protein (c-Myc) (1:500; cat. no. 10828-1-AP; ProteinTech Group, Inc.) and GAPDH (1:3,000; cat. no. 60004-1-Ig; ProteinTech Group, Inc.). Secondary antibodies, goat anti-rabbit IgG (1:8,000; cat. no. 10285-1-AP; Cell Signaling Technology, Inc.) and goat anti-mouse IgG (1:8,000; cat. no. SA00001-1; Cell Signaling Technology, Inc.) were then incubated with the membrane for 1 h at RT. Signals were detected using an ECL detection reagent (Santa Cruz Biotechnology, Inc.). Images of the band images were captured and quantified using the ChemiDoc™ XRS+ system (Bio-Rad Laboratories). ImageJ version 1.52a software (National Institutes of Health) was used to analyze the greyscale values of the protein bands.

**RNA isolation and reverse transcription-quantitative (RT-q)PCR.** Total RNA were extracted from of SSP, SSP-EV, SSP-ABCG2, SSP-sh-control, SSP-ABCG2-sh1, SSP-ABCG2-sh2 and SSP-ABCG2-sh3 cells with TRIzol® reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The NanoDrop 2000 (Thermo Fisher Scientific, Inc.) was used to confirm the concentration and purity of abstracted RNA. The PrimeScript™ RT reagent kit with gDNA Eraser (cat. no. RR047Q; Takara Biotechnology Co., Ltd.) was used to synthesize cDNA from 1 µg total RNA according to the manufacturer's instructions. qPCR was performed using SYBR Premix Ex Taq II (cat. no. RR820A) in StepOnePlus™ (Thermo Fisher Scientific, Inc.). The results were amplified using the following conditions: 40 Cycles at 95°C for 2 min, 95°C for 10 sec, 60°C for 40 sec. The relative mRNA expression of each group was normalized to β-actin and were calculated by 2-ΔΔCq method (22). The ABCG2 primer sequences included sense primer (5’-TTCAGTACTTCCAGCTTCCAGAT-3’) and antisense primer (5’-ATTGGTTTCCGTGTCATTGAG-3’). The β-actin primer sequences included sense primer (5’-GCACCTTTCCAGCCTTCCCTCC-3’) and antisense primer (5’-TCACCTTCCAGGTCTCCAGTTTT-3’).

**Cell apoptosis assay.** The SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells were collected in the 1x binding buffer (cat. no. 556454; BD Biosciences) at a concentration of 1x10⁶ cells/ml after 48 h serum-free culture at 37°C. In total, 5 µl of APC Annexin V (cat. no. 561012; BD Biosciences) was used for staining for 15 min at RT in the dark. Next, 400 µl of 1x binding buffer and 5 µl of 7-AAD (cat. no. 559925; BD Biosciences) was added to each tube for the exclusion of non-viable cells. Cells were analyzes using flow cytometry with the FACScantoII and FACSDiva software version 6.1.2 (BD Biosciences). The results were exported using FlowJo™ version 10 software (FlowJo LLC).

**Transwell assay.** A total of 1x10⁶ cells from the four lentiviral transfection groups in the logarithmic growth phase were plated in serum-free RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) at 37°C overnight. The cells were resuspended in serum-free, IL-2-free RPMI-1640 medium and adjusted to a cell density of 1.5x10⁵ cells/ml. Cell suspension (200 µl) was added to the upper Transwell chamber, and 700 µl RPMI-1640 medium was added to the lower chamber. The migration of the underlying cells was observed under a light microscope (50x magnification; DMI400B; Leica Microsystems GmbH) after 24 h, cells in the lower compart- ment were collected and measured using the aforementioned CCK-8 method to evaluate migrated cells using a Multiskan FC microplate reader (absorbance: 450 nm, Thermo Fisher Scientific, Inc.).

**Clone formation experiment.** Four groups of cells were adjusted to a concentration of 1x10⁴ cells/ml. 90 µl of methylcellulose clone (Methylcellulose cell cloning kit; GENMED SCIENTIFICS INC, USA, GMS10003) was added to the suspension (clone:cell suspension, 9:1), and the cells were incubated in a 37°C water bath for 15 min. The cells were diluted (1:9) for testing, and the contents were mixed by shaking and transferred to a 24-well culture plate at 1 ml per well. Cells were incubated at 37°C for 5 days. Images were captured using a light microscope (50x magnification; DMI400B; Leica Microsystems GmbH).

**In vivo transplantation to BALB/c nude mice.** Animal experiments were approved by the Ethics Committee of Scientific Research/Medicine Clinical Trial of The First Affiliated
Paraffin-embedded sections were captured using a light microscope (200x magnification, DMI400B; Leica Microsystems GmbH) and analyzed using the automatic light control (light 12 h, dark 12 h), temperature 22°C, relative humidity 60% and standard sterile laboratory diet (23) for 5 days before the experiment. Animal health was checked prior to before tumor grouping and implantation to ensure that the mice were disease-free. During the course of the experiment, animals were monitored once a day for laboratory condition, environment, dietary supply, mouse growth, activity and tumor burden. The mice were divided into four groups named SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH at random and injected separately with SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells with 1x10^7/100 μl of serum-free RPMI-1640 medium in the same volume of Matrigel (BD Biosciences) into the right back side flank regions. The SSP-EV group was the negative control. When tumors were ~0.5 cm, gemcitabine (0.15 μg/ml, once every 5 days, intraperitoneally, Sigma-Aldrich; Merck KGaA) was used for drug intervention. As the tumor grew, the volume and weight were measured and recorded once a day with the following established formula: Tumor size = (L1xL2^2)/2, where L1 is the long axis and L2 is the short axis of the tumor. Thirty days post cell injection, the largest tumor volume reached ~2,000 mm^3 and no mice died. The mice were humanely sacrificed by cervical dislocation, and tumor samples were harvested by standard forceps, scissors and surgical blades for further analysis.

**Immunohistochemistry (IHC).** Paraffin-embedded sections from xenograft tumors which were cut into 5-μm sections and were heated at 55°C for deparaffinization. Remove the wax with xylene three times (20 min each time), and rehydrate the section with absolute ethanol for 10 min, 95% ethanol (diluted with distilled water) for 5 min and 80% ethanol for 5 min. Rinse with distilled water 3 times. After antigen retrieval, the slides were incubated with the corresponding antibodies: Caspase 3 (1:50; cat. no. 19677-1-AP; ProteinTech Group, Inc.), Bax (1:400; cat. no. 5023; Cell Signaling Technology, Inc.), BCL2 (1:400; cat. no. 15071; Cell Signaling Technology, Inc.), c-Myc (1:400; cat. no. ab32072; Abcam), CD56 (1:2,000; cat. no. 14255-1-AP; ProteinTech Group, Inc.), CD3 (1:200; cat. no. 17617-1-AP; ProteinTech Group, Inc.) and Nucleolysin TIA-1 isoform p40 (TIA 1) (1:100; cat. no. 12133-2-AP; ProteinTech Group, Inc.) and Nucleolysin TIA-1 isoform p40 (TIA 1) (1:100; cat. no. 12133-2-AP; ProteinTech Group, Inc.) at 4°C overnight. Following this, sections were incubated with Mouse and Rabbit-specific HRP/DAB (ABC) from the Mouse and Rabbit specific HRP/DAB (ABC) Detection IHC kit (cat. no. ab64264; Abcam). Epstein-Barr virus (EBV) DNA transcripts were performed using the RISH Epstein Barr encoded RNA probe kit (ISH-6022-Y, 170510; OriGene Technologies, Inc.). Images were captured using a light microscope (200x magnification, DMI400B; Leica Microsystems GmbH) and analyzed using ImageJ version 1.52a software (National Institutes of Health).

**Statistical analysis.** SPSS version 21.0 (IBM, Corp.) and GraphPad Prism version 7.0 were used to analyze the data. All data are reported as the mean ± SD (unless otherwise shown). Comparisons between and among groups were performed with unpaired two-tailed Students t-test and one-way analysis of variance (ANOVA) followed by Bonferroni’s correction for multiple comparisons. IC₅₀ values were calculated using the linear regression method. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**ABCG2 is upregulated in SSP cells.** Increasing evidence indicates that SP cells are vital in cancer relapse (9,15). Our previous study showed SSP cells provided a new perspective to better understand the mechanisms of MDR in ENKL (15). However, the function of ABCG2 in SSP cells is unclear. To address this question, the expression of ABCG2 was measured. As expected, immunofluorescence (Fig. 1A and B) and western blotting (Fig. 1C) results showed that the expression of ABCG2 protein was significantly upregulated in SSP cells compared with SNK-6 cells (P<0.001). The specific properties of lymphocytic surface markers in SSP cells were analyzed. Flow cytometry showed SSP cells had NK-cell phenotype (CD56+, CD3-, CD8-, CD5-, CD16-, Granzyme B+ and Perforin+) compared with negative control (Fig. S1).

To further validate the effect of ABCG2 in on the proliferation of SSP cells, SSP cells were infected with a recombinant lentiviral vector, empty vector sequence of lentivirus for negative control (SSP-EV), lenti-ABCG2 for ABCG2 overexpression (SSP-ABCG2), lenti-sh negative control (SSP-sh-control) and three types of lenti-ABCG2 shRNAs for downregulation. Then, western blotting (Fig. 1D) and RT-qPCR (Fig. 1E) were used to screen out the most efficient cells (ABCG2-sh3, referred to as SSP-ABCG2-SH). In order to determine whether the cell proliferation caused by ABCG2 was due to its pro-proliferation effect or weakening of the antiproliferative effect of the drugs in SSP cells (due to the efflux activity of ABCG2), a CCK-8 assay was performed. The OD values among the five groups presented the same trend and were not significantly different (P>0.05; Fig. 1F), which showed that ABCG2 had no role in the proliferation of SSP cells without drug action. Collectively, these data suggested the expression of ABCG2 increased in SSP cells and ABCG2 had no effect on cell proliferation.

Altering the expression of ABCG2 can affect the drug resistance of SSP cells. The CCK-8 method was used to verify the MDR.
First, the impact of doxorubicin in the five groups was detected and it was observed that the inhibition rate of SSP-ABCG-SH was significantly higher compared with the SSP‑EV and the SSP-sh-control group (P<0.05) under the same drug concentration (Fig. 2B). The SSP-EV and SSP-sh-control groups were both controls of the SSP-ABCG2 and SSP-ABCG2-SH groups, respectively, and these treatments both did not impact ABCG2 expression (Fig. 1D and E) or proliferation (Fig. 1F and 2B) regardless of drug intervention. SSP-EV was used for comparison in the following experiments because SSP-sh-control was only to ensure the specificity of ABCG2 shRNA (Fig. 1D, E) and to exclude potential interference of random sequence in the proliferation assay under drug (Fig. 2B) or not (Fig. 1F). Following treatment with cytarabine, cisplatin and gemcitabine, the inhibition rates of SSP-ABCG2 cells were lower compared with SSP-EV cells (P<0.05) with the same trend under doxorubicin (Fig. 2A, C and D). Furthermore, the IC50 value of the cytarabine in SSP-ABCG2 cells killed 50% SSP-ABCG2 cells, but killed 90% SSP-ABCG2-SH cells (Fig. 2A). Therefore, SSP-ABCG2-SH cells had increased sensitivity to cytarabine compared with SSP-ABCG2 cells. In contrast, the inhibition rate difference did not exist in the four transfection groups treated with l-asparaginase (Fig. 2E).

The IC50 values of the four transfection groups of cells were determined and the drug sensitivity was determined using the IC50 values. As shown in Table I and Fig. 2F and G, when treated with doxorubicin, SSP-ABCG2 cells had a low level of sensitivity, with a significantly relatively higher IC50 value of 107.29±1.77 compared with the SSP and SSP-EV cells (IC50 values were 80.88±1.55 and 78.55±0.89), respectively, and SSP-ABCG2-SH cells were significantly highly sensitive, with an IC50 value of 38.29±2.59 (P<0.01). The IC50 values in cytarabine, cisplatin and gemcitabine presented the same trend as doxorubicin. In summary, SSP-ABCG2 cells were significantly less sensitive (higher IC50 values) under doxorubicin, cytarabine, cisplatin and gemcitabine compared with SSP-EV cells, and SSP-ABCG2-SH cells were significantly sensitive. However, the IC50 values of l-asparaginase showed no change among the four transfection groups. In other words, these results indicated that l-asparaginase had not been affected to MDR mechanisms in SSP cells compared with doxorubicin, cytarabine, cisplatin and gemcitabine.

Additionally, further tests were performed to determine whether the combination of two drugs can decrease drug resistance characteristics of cells. Notably, the results showed that the incorporation of two drugs still did not eliminate the
Figure 2. Altering the expression of ABCG2 can affect the drug resistance of SSP cells. SSP, SSP-EV, SSP-ABCG2, SSP-ABCG2-SH cells were separately treated with (A) cytarabine, (B) doxorubicin, (C) cisplatin, (D) gemcitabine and (E) l-asparaginase. (A-E) show drug inhibition curves at various concentrations. The IC50 values among the four cell lines treated with cytarabine and gemcitabine (F) and doxorubicin, cisplatin and l-asparaginase (G) are shown. Effects of the combined use of the (H and I) cisplatin-gemcitabine group and (J and K) doxorubicin-gemcitabine are presented in the SSP-EV cells (H and J) and SSP-ABCG2 cells (I and K). Data are shown as the mean ± SD, n=3. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. ABCG2, ATP-binding cassette subfamily G member 2; SSP, side population cells-SNK-6/ADM-SP; sh, short hairpin.
Figure 3. Pelitinib can overcome multidrug resistance induced by ABCG2. (A) The inhibition rate of doxorubicin in SSP-EV and (B) SSP-ABCG2 cells under the action of the inhibitor pelitinib. The inhibition rates of gemcitabine in (C) SSP-EV and (D) SSP-ABCG2 cells under pelitinib are shown. (E and F) IC₅₀ values of the two drugs under pelitinib. Data are shown as the mean ± SD, n=3. *P<0.05, ***P<0.001 vs. SSP-EV cells.

Table I. IC₅₀ values of four different cell lines treated with five different chemotherapy drugs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>SSP cells</th>
<th>SSP-EV cells</th>
<th>SSP-ABCG2 cells</th>
<th>SSP-ABCG2-SH cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>80.880±1.551</td>
<td>78.556±0.892</td>
<td>107.293±1.771*</td>
<td>38.299±2.591*</td>
</tr>
<tr>
<td>Cytarabine</td>
<td>1,800.598±4.832</td>
<td>1,788.376±8.241</td>
<td>3,900.468±5.772c</td>
<td>599.810±2.572c</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>52.213±4.092</td>
<td>51.827±5.773</td>
<td>77.723±1.652a</td>
<td>10.983±3.669a</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>0.130±0.002</td>
<td>0.140±0.005</td>
<td>0.228±0.005b</td>
<td>0.043±0.001c</td>
</tr>
<tr>
<td>l-asparaginum</td>
<td>18.950±1.081</td>
<td>18.770±1.338</td>
<td>18.000±0.988</td>
<td>17.880±0.771</td>
</tr>
</tbody>
</table>

Data are shown as the mean ± SD. *P<0.01, **P<0.001, ***P<0.0001 vs. SSP-EV cells.
Table II. IC_{50} values of SSP-EV and SSP-ABCG2 cell lines treated with different concentration of Pelitinib combined with Doxorubicin and Gemcitabine.

<table>
<thead>
<tr>
<th>Drug</th>
<th>SSP-EV cells</th>
<th>SSP-ABCG2 cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>78.819±1.640</td>
<td>106.786±1.660</td>
</tr>
<tr>
<td>Doxorubicin+0.75 µM Pelitinib</td>
<td>76.813±0.770</td>
<td>112.657±2.990</td>
</tr>
<tr>
<td>Doxorubicin+1.5 µM Pelitinib</td>
<td>75.307±0.890</td>
<td>72.828±0.770*</td>
</tr>
<tr>
<td>Doxorubicin+3 µM Pelitinib</td>
<td>73.563±1.220</td>
<td>40.895±1.390*</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>0.149±0.010</td>
<td>0.225±0.007</td>
</tr>
<tr>
<td>Gemcitabine+0.75 µM Pelitinib</td>
<td>0.156±0.009</td>
<td>0.221±0.008</td>
</tr>
<tr>
<td>Gemcitabine+1.5 µM Pelitinib</td>
<td>0.144±0.001</td>
<td>0.154±0.009*</td>
</tr>
<tr>
<td>Gemcitabine+3 µM Pelitinib</td>
<td>0.151±0.020</td>
<td>0.053±0.001**</td>
</tr>
</tbody>
</table>

Data are shown as the mean ± SD. *P<0.001 vs. Doxorubicin in SSP-ABCG2 cells, **P<0.05 vs. Gemcitabine in SSP-ABCG2 cells, ***P<0.001 vs. Gemcitabine in SSP-ABCG2 cells.

Figure 4. ABCG2 increases the proliferation and migration of gemcitabine-treated SSP cells. (A) Colony formation experiments (×50 magnification). Scale bar, 500 µm. (B) Transwell assays (×50 magnification). Scale bar, 50 µm. (C) EDU assays and (D) apoptosis analyses were performed using SSP cells with different ABCG2 expression levels after treatment with gemcitabine. (E) Western blotting was used to analyze different levels of apoptosis-related proteins (BCL2, Bax, BAD and c-Myc) in SSP, SSP-EV, SSP-ABCG2 and SSP-ABCG2-SH cells. Data are shown as the mean ± SD, n=3. *P<0.05, ***P<0.01, """"P<0.001. ABCG2, ATP-binding cassette subfamily G member 2; SSP, side population cells-SNK-6/ADM-SP; c-Myc, Myc proto-oncogene protein; APC, APC Annexin V.
multidrug resistance induced by ABCG2. The inhibition rates of SSP-ABCG2 cells (Fig. 2I and K) were far lower compared with the results of the SSP-EV cells (Fig. 2H and G), which showed no difference between treatment with cisplatin-gemcitabine group or doxorubicin-gemcitabine. Pelitinib can overcome MDR induced by ABCG2. Once the potent effect of ABCG2 on MDR was observed, pelitinib, which is an inhibitor of ABCG2 (24-26), was selected to test the effects on SSP cells. Pelitinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor, has been demonstrated to notably inhibit ABCG2 efflux activity by interfering with their ATPase activity (24) without the ABCG2 protein levels being impacted (25,26).

As shown in Fig. 3A-D, the inhibition rates of doxorubicin and gemcitabine were found to be enhanced by pelitinib in the SSP-ABCG2 cells in a concentration-dependent manner. In ABCG2-overexpression cells, the IC₅₀ values of doxorubicin (Fig. 3E) and gemcitabine (Fig. 3F) were significantly declined in the presence of increasing pelitinib concentrations (Table II). The IC₅₀ values could immune from 0.75 μM Pelitinib both in doxorubicin and gemcitabine (P>0.05). However, as shown in Table II when the concentration reached 1.5 μM, the IC₅₀ values were significantly lower compared with non-pelitinib groups (P<0.05). The results suggested that pelitinib was resistant to the efflux mechanism of ABCG2, so that lower concentrations of the drugs could also kill the cells.

ABCG2 influences the proliferation and migration of gemcitabine-treated SSP cells. The results of the colony formation experiment (Fig. 4A) showed that the SSP-ABCG2 cells presented significantly higher density growth (P<0.0001) compared with SSP-EV cells, and the cytoplasm was bright, regular and round after treatment with gemcitabine. In contrast, SSP-ABCG2-SH cells showed significantly decreased cell proliferation (P<0.0001) compared with SSP-EV cells, and almost lost the ability to form colonies. Then, Transwell
assays were used to determine migration (Fig. 4B). The results indicated that ABCG2-knockdown decreased cell migration significantly compared with the SSP-EV cells (P<0.05).

EdU assays were conducted to investigate how ABCG2 regulated cell proliferation in gemcitabine-treated cells. It was demonstrated that SSP-ABCG2 cells significantly accounted for a larger proportion of cells in the log growth phase compared with SSP-EV cells (P<0.0001), and SSP-ABCG2-SH cells was significant far less compared with in SSP-EV cells (P<0.0001) (both Fig. 4C).

To examine whether ABCG2 has a functional role in regulating apoptosis with gemcitabine, flow cytometry was used. It was found that SSP-ABCG2-SH significantly induced apoptosis (P<0.001) and increasing the expression of ABCG2 decreased the rate of apoptosis significantly (P<0.001) (Fig. 4D). Then, the expression of apoptosis-associated genes was investigated in gemcitabine-treated cells. It was shown that pro-apoptotic proteins, such as Bax and Bad (27), were significantly upregulated (Fig. 4E) and anti-apoptotic proteins, such as BCL2 and C-myc (28), were significantly downregulated in ABCG2 overexpression cells compared with SSP-EV cells (P<0.05).

**Altered ABCG2 expression significantly affects SSP tumor growth under the action of gemcitabine in vivo.** In order to determine the role of ABCG2 on tumorigenicity, four groups of cells were injected into nude mice and tumor incidence was assessed. All mice developed tumors within half a month. When tumors were ~0.5 cm, they were treated with gemcitabine for 3 weeks. There was a significant inhibition of tumor volume (P<0.05; Fig. 5A) and weight (P<0.0001; Fig. 5C) in the SSP-ABCG2-SH cell group compared with the SSP-EV group, which is higher in mice injected with SSP‑ABCG2 cells (P<0.05; both Fig. 4C).

When tumors were ~0.5 cm, they were treated with gemcitabine for 3 weeks. There was a significant inhibition of tumor volume (P<0.05; Fig. 5A) and weight (P<0.0001; Fig. 5C) in the SSP-ABCG2-SH cell group compared with the SSP-EV group, which is higher in mice injected with SSP‑ABCG2 cells (P<0.05; both Fig. 4C).

**Discussion**

Of patients with ENKL, ~70% present with localized or early-stage disease, and despite the improvements of radiation therapy and chemotherapy, relapse occurs in ≤50% of patients with refractory and disseminated disease (4,5,29). The present study sought to exploit the upregulation of ABCG2 in SSP cells in vivo and in vitro, and utilize the combination of peltinib with conventional anticancer drugs to specifically eradicate ENKL cancer cells. Most traditional chemotherapy drugs, such as doxorubicin, cytarabine, cisplatin and gemcitabine, could not overcome the drug resistance of SSP-ABCG2 cells, apart from l-asparaginasum, and even the combination of two drugs did not alleviate MDR.

SSP cells sorted from SNK-6 cells have been verified to exhibit the NK-cell phenotype (15). The xenograft tumors of SSP cells have also been detected the CD56+, TIA1+ and CD3- by IHC, Granzyme B+ and Perforin+ using flow cytometry, and EBER+ by in situ hybridization for EBV RNA. These lymphocytic surface molecular markers demonstrated the ENKL characteristics of these xenograft tumors.

Several studies have revealed that ABCG2 can be undoubtedly used as a biomarker to predict recurrence and poor outcomes in colon cancer (25,30-33). ABCG2-knockdown can also enhance the effect of cisplatin and attenuate the migration and invasion of squamous cell carcinoma (34). Therefore, targeting the ABC transporter superfamily and restoring sensitivity to chemotherapy has become an important goal for overcoming clinical drug resistance in cancer (35,36).

Several TKIs have been found to inhibit ABCG2. Afatinib leads to the methylation of the ABCG2 promoter and enhances the efficacy of conventional chemotherapeutic agents (37-39). One study revealed that ceritinib notably enhanced the efficacy of doxorubicin and paclitaxel in breast cancer (40). These studies were consistent with the results of the present study, which found that peltinib can effectively increase tumor chemotherapy sensitivity by attenuating efflux activity in ENKL.

The association between ABCG2 and tumor characteristics has also been widely reported in various cancer types. ABCG2 was positively correlated with the abnormal activation of NF-xB in breast cancer (41) and matrix metalloproteinase 9 in glioma stem cells (42), but played a protective role against oxidative stress and inflammatory factors in colorectal cancer (43). It was of note that the relationship between the Wnt family and ABCB1 was also enhanced by reducing ABCB1 (44). Then researchers demonstrated that Wnt/β-catenin signaling reversed multi-drug resistance of cholangiocarcinoma by reducing ABCB1 (48). Then researchers demonstrated that Wnt/β-catenin signaling could be positively regulated by secreted frizzle-related protein 5 gene methylation in leukemia (44), retinoic acid receptor γ in colorectal cancer (45) and FZD1 in ovarian cancer (49) and negatively regulated by miR-506 in colorectal cancer (47).

Knockdown of disheveled, a key mediator of Wnt/β-catenin, sensitized cisplatin-resistant
lung cancer cells through inhibiting ABCG2, ABCC, and ABCB1 (46). Therefore, it would be of value to investigate the relationship between ABCG2, Wnt/β-catenin and related regulatory genes in ENKL in the future.

However, the primary limitation of the present study is the lack of clinical tissue validation, although experiments conducted in vitro and in vivo demonstrated the ENKL properties of cell line and xenograft tumors (CD3-, CD5-, CD8-, CD56+, CD16-, Granzyme B+, EBER+ and Perforin+). In the future, specimens from patients with ENKL should be used for pathological examination to detect ABCG2 expression and to guide treatment decisions according to pathological results. A study investigating the efficacy of drugs targeting ABCG2 would be preferable to validate the present results and this will be a focus of our future research.

In summary, the present study has provided additional insight to the MDR mechanisms of ENKL. It has been proposed that ABCG2 could be a promising biomarker for the identification of SP cells and a new therapeutic target for the eradication of SP cells due to its contribution to drug resistance, cell proliferation, apoptosis inhibition, distant metastasis and disease recurrence. Novel strategies targeting ABCG2 warrant further investigation. Such strategies could effectively circumvent drug resistance and eliminate the functions of SP cells to achieve improved cancer treatment.

Acknowledgements

Not applicable.

Funding

This study was supported in part by the National Natural Science Foundation of China (grant no. 81700187) and Henan Medical Science and Technology Research Project (grant no. 201702017).

Availability of data and materials

The data and materials in the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

SW and QC designed the study. SW, MD and ZY performed the experiments. SW analyzed experimental data and wrote the paper. QC and XZ revised the manuscript. All authors approved the final manuscript.

Ethics approval and consent to participate

Animal experiments were approved by the Ethics Committee of Scientific Research/Medicine Clinical Trial of The First Affiliated Hospital of Zhengzhou University (approval no. SS-2018-18; Zhengzhou, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


29. de Mel S, Hue SSS, Jeyasekharan AD, Chng WJ and Ng SB: Methylation of SFRP5 is related to multidrug resistance in ABCB1- and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. Biochem Pharmacol 97: 27-37, 2015.


